Related Experiment Videos
Gemeprost versus misoprostol for cervical priming before first-trimester abortion: a randomized controlled trial
E Ekerhovd1, N Radulovic, A Norström
1Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Göteborg University, Göteborg. erling.ekerhovd@obgyn.gu.se
Obstetrics and Gynecology
|April 10, 2003
Summary
Misoprostol (400 mcg) and gemeprost (1 mg) demonstrate comparable efficacy for cervical priming via vaginal administration before first-trimester abortion procedures. Both agents effectively prepare the cervix for vacuum aspiration, showing no significant differences in dilation force.
Area of Science:
- Obstetrics and Gynecology
- Reproductive Medicine
Background:
- Cervical priming is crucial for facilitating surgical abortion procedures.
- Pharmacological agents are used to achieve cervical dilation before surgical termination.
Purpose of the Study:
- To compare the efficacy of vaginal misoprostol (400 mcg) versus gemeprost (1 mg) for cervical priming.
- To evaluate cervical dilation force parameters before first-trimester vacuum aspiration abortion.
Main Methods:
- Prospective controlled trial involving 90 nulliparous women undergoing first-trimester abortion.
- Randomized administration of either misoprostol or gemeprost vaginally 3-4 hours prior to procedure.
- Cervical dilation force measured using a cervical tonometer and Hegar dilators (3-10 mm).
Main Results:
- No significant difference in baseline cervical dilation between misoprostol and gemeprost groups.
- Comparable peak and cumulative forces required for cervical dilation to 10 mm between the two treatment groups.
- Both agents demonstrated similar effectiveness in cervical priming.
Conclusions:
- Vaginal misoprostol (400 mcg) is a similarly effective cervical priming agent as gemeprost (1 mg).
- These findings support the use of misoprostol for cervical preparation prior to first-trimester surgical abortion.